alexa Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis.


Journal of Clinical & Experimental Ophthalmology

Author(s): Caspi RR

Abstract Share this page

Abstract Experimental autoimmune uveoretinitis (EAU) in animals can be induced by immunization with retinal antigens or their fragments and represents human uveitis of putative autoimmune origin. The pathogenesis of EAU, and likely also of human uveitis, involves cell-mediated destruction of retinal tissues that is dependent on retinal antigen-specific T cells. Because in most cases a Th1-type response has been implicated in pathogenesis, the prevailing consensus has been that immunoregulatory manipulations designed to enhance the Th2 response at the expense of the Th1 response will be beneficial in clinical treatment of uveitis. This assumption may not always be correct. The present review will summarize the evidence that, despite a central role for Th1 response in uveitis, an unopposed Th2-like response can be equally or more destructive to the retinal tissues. Furthermore, the Th1 response itself triggers regulatory circuits that feed back and dampen further recruitment of antigen-specific T cells into the Th1 effector pool. Thus, although the Th1 effector response can and does result in retinal pathology, immunoregulatory strategies must take into account that immune deviation therapies designed to replace the Th1 with a Th2 response might result in exchanging one type of pathology for another rather than in achieving the desired therapeutic effect.
This article was published in Int Rev Immunol and referenced in Journal of Clinical & Experimental Ophthalmology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version